Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

The combo therapy demonstrated an ORR of 87%, with a complete response rate of 65% and a partial response rate of 23%.

In this video, Jeremy S. Abramson, MD, discusses 2-year results from the phase 3 STARGLO trial, which were presented at ASCO ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

“Building on Columvi’s established benefits, [this] data demonstrate[s] the potential of this combination regimen to improve ... into the first-line DLBCL setting. To that end, Roche is ...